About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

NCT07150845·29 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Evommune, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Chronic AD that has been present for ≥6 months
Validated-Investigator's Global Assessment score of ≥3
EASI of ≥16
BSA of AD involvement of ≥10%

You may not be if

Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
Use of certain medications
Presence of skin comorbidities or other condition(s) that may interfere with study assessments
Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

The record

StatusCompleted

PhasePhase 2

Taking part121

StartedAug 2025

UpdatedOct 5, 2026

Conditions

Atopic Dermatitis

Where29

Saguaro Dermatology
Phoenix, Arizona, United States
Center for Dermatology Clinical Research
Fremont, California, United States
Metropolis Dermatology - Downtown Los Angeles
Los Angeles, California, United States

Clareo Health | Phase 2b Study of EVO756 in Adults With Atopic Dermatitis